HC Wainwright Issues Positive Outlook for TNGX Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – HC Wainwright lifted their Q3 2026 earnings estimates for Tango Therapeutics in a research note issued on Tuesday, June 9th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.26) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.27) EPS and FY2026 earnings at ($1.15) EPS.

Several other research analysts also recently commented on the company. UBS Group set a $55.00 target price on Tango Therapeutics in a research note on Thursday, May 14th. Canaccord Genuity Group boosted their target price on Tango Therapeutics from $30.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings downgraded Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. Citigroup reissued a “buy” rating on shares of Tango Therapeutics in a research note on Monday, April 27th. Finally, Guggenheim boosted their target price on Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.42.

Tango Therapeutics Trading Down 9.1%

Shares of NASDAQ TNGX opened at $28.68 on Thursday. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -34.55 and a beta of 1.19. Tango Therapeutics has a 12 month low of $4.32 and a 12 month high of $32.79. The stock has a 50-day moving average price of $23.09 and a two-hundred day moving average price of $16.13.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics in the fourth quarter valued at approximately $35,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after buying an additional 4,464 shares during the period. ANTIPODES PARTNERS Ltd acquired a new position in shares of Tango Therapeutics in the fourth quarter valued at approximately $40,000. State of Wyoming acquired a new position in shares of Tango Therapeutics in the first quarter valued at approximately $128,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Tango Therapeutics by 52.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after buying an additional 2,243 shares during the period. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insider Activity

In other news, insider Adam Crystal sold 38,460 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $25.00, for a total value of $961,500.00. Following the completion of the transaction, the insider owned 112,622 shares of the company’s stock, valued at $2,815,550. This represents a 25.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 131,460 shares of company stock valued at $2,965,920 over the last three months. Corporate insiders own 6.50% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.